Share chart Ikena Oncology, Inc.
Extended chart
Simple chart
About Ikena Oncology, Inc.
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. more detailsMain settings
| IPO date | 2021-03-26 |
|---|---|
| ISIN | US45175G1085 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | link |
| Change price per day: | -1.28% (1.175) |
|---|---|
| Change price per week: | +0.8696% (1.15) |
| Change price per month: | -8.66% (1.27) |
| Change price per 3 month: | -15.33% (1.37) |
| Change price per half year: | -31.36% (1.69) |
| Change price per year: | -30.54% (1.67) |
| Change price per 3 year: | -64.74% (3.29) |
| Change price per year to date: | -24.18% (1.53) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 9.52 | 1 |
| P/BV | 0.6285 | 10 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -29.52 | 0 |
| ROE, % | -33.3 | 0 |
| ROIC, % | 0 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.1275 | 10 |
| Debt/Ratio | 0.0531 | 10 |
| Debt/Equity | 0.1237 | 10 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | -33.62 | 0 |
| Yield Ebitda, % | 33.42 | 5 |
| Yield EPS, % | -20.3 | 0 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Orbimed Advisors LLC. | 9 907 945 | 20.53 |
| Atlas Venture Life Science Advisors, LLC | 5 018 178 | 10.4 |
| BVF Inc. | 4 769 164 | 9.88 |
| FMR, LLC | 4 184 293 | 8.67 |
| Omega Fund Management, Llc | 2 249 123 | 4.66 |
| Blue Owl Capital Holdings LP | 1 953 616 | 4.05 |
| Blackrock Inc. | 1 858 156 | 3.85 |
| Vanguard Group Inc | 1 524 848 | 3.16 |
| Verition Fund Management, LLC | 1 322 397 | 2.74 |
| Artal Group S.A. | 999 513 | 2.07 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Mark Manfredi Ph.D. | President, CEO & Director | 810.69k | 1971 (54 years) |
| Dr. Jotin Marango M.D., Ph.D. | CFO & Head of Corporate Development | 577.12k | 1979 (46 years) |
| Mr. Bob Lally | Senior Vice President of Finance & Operations | N/A | |
| Mr. Jeffrey Ecsedy Ph.D. | Chief Development Officer | N/A | 1970 (55 years) |
| Mr. David Damphousse M.S. | Senior Vice President of Clinical Development Operations | N/A | |
| Mr. Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations | N/A | |
| Dr. Caroline Germa M.D., Ph.D. | Chief Medical Officer | N/A | 1972 (53 years) |
| Ms. Rebecca Cohen | Vice President of Investor Relations, Corporate Strategy & Communication |
About company
Address: United States, Boston. MA, 645 Summer Street - Open in google maps, Open in yandex maps
Website: https://ikenaoncology.com
Website: https://ikenaoncology.com
